review_heavy
Review literature is very dense relative to primary central evidence.
supportedtopmoderate inflation risk
Saccharomyces
inflammatory bowel disease
Saccharomyces looks like a credible signal in inflammatory bowel disease, though some caution is still warranted.
Saccharomyces shows a moderate evidence base in inflammatory bowel disease, with multiple central papers and additional supporting literature.
saccharomyces
Credibility score
66
Human translation
3/5
Reproducibility
5/5
Novelty
1/5
Actionability
3/5
Credibility 66Human translation 3/5Reproducibility 5/5Novelty 1/5Actionability 3/5
Why this scores the way it does
- moderate central evidence base
- dense review literature
Main caveats
- directionality and confounding still require curated review
Internal review flags
1 flagsPrimary central evidence
14 papersPediatric inflammatory bowel disease: clinical and therapeutic aspects.
2001Current opinion in gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fungal microbiota dysbiosis in IBD.
2017Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Celiac disease-specific and inflammatory bowel disease-related antibodies in patients with recurrent aphthous stomatitis.
2019Immunobiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Inflammatory Bowel Disease Serological Immune Markers Anti-Saccharomyces cerevisiae Mannan Antibodies and Outer Membrane Porin C are Potential Biomarkers for Hirschsprung-associated Enterocolitis.
2019Journal of pediatric gastroenterology and nutrition
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Variation of Gut Mucosal Microbiome With Anti-Saccharomyces cerevisiae Antibody Status in Pediatric Crohn Disease.
2019Journal of pediatric gastroenterology and nutrition
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α.
2022Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Individuals with Inflammatory Bowel Disease Have an Altered Gut Microbiome Composition of Fungi and Protozoa.
2022Microorganisms
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection.
2023Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Phage-display immunoprecipitation sequencing of the antibody epitope repertoire in inflammatory bowel disease reveals distinct antibody signatures.
2023Immunity
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Alterations in the Fungal Microbiome in Ulcerative Colitis.
2023Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fungal Microbiota Composition in Inflammatory Bowel Disease Patients: Characterization in Different Phenotypes and Correlation With Clinical Activity and Disease Course.
2024Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
In vitro fermentation of yeast cell walls (mannan-oligosaccharide) and purified β-glucans modulates the colonic microbiota of dogs with inflammatory bowel disease and demonstrates protective effects on barrier integrity and anti-inflammatory properties.
2025PloS one
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Mycobiota dynamics in inflammatory bowel disease: Fungal biomarkers and Clostridioides difficile co-infection.
2025Microbial pathogenesis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal Mycobiota in Patients with Inflammatory Bowel Diseases and Extraintestinal Manifestations.
2024Gut microbes reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
8 papersMAGI2 genetic variation and inflammatory bowel disease.
2009Inflammatory bowel diseases
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course.
2015Journal of Crohn's & colitis
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Inflammatory bowel diseases and Takayasu's arteritis: coincidence or association?
2016International journal of rheumatic diseases
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Anti-food and anti-microbial IgG subclass antibodies in inflammatory bowel disease.
2016Scandinavian journal of gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
IgE-Dependent Food Sensitisation and Its Role in Clinical and Laboratory Presentation of Paediatric Inflammatory Bowel Disease.
2023Nutrients
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Comprehensive Association Analyses of Extraintestinal Manifestations in Inflammatory Bowel Disease.
2024Gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Attenuation of inflammatory bowel disease by oral administration of mucoadhesive polydopamine-coated yeast β-glucan via ROS scavenging and gut microbiota regulation.
2024Journal of nanobiotechnology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Yeast-Inspired Orally-Administered Nanocomposite Scavenges Oxidative Stress and Restores Gut Immune Homeostasis for Inflammatory Bowel Disease Treatment.
2025ACS nano
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
34 papersInflammatory bowel disease.
2002Endoscopy
Relevant review or meta-analysis for the signal-disease area.
Probiotics and inflammatory bowel disease.
2003BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Relevant review or meta-analysis for the signal-disease area.
Indeterminate colitis.
2003Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis?
2004Clinical & developmental immunology
Relevant review or meta-analysis for the signal-disease area.
Serologic markers in inflammatory bowel disease.
2006Clinical chemistry
Relevant review or meta-analysis for the signal-disease area.
Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.
2008British journal of clinical pharmacology
Relevant review or meta-analysis for the signal-disease area.
Behçet's syndrome.
2008Best practice & research. Clinical rheumatology
Relevant review or meta-analysis for the signal-disease area.
Saccharomyces boulardii in childhood.
2009European journal of pediatrics
Relevant review or meta-analysis for the signal-disease area.
Probiotics.
2009Indian journal of medical microbiology
Relevant review or meta-analysis for the signal-disease area.
The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.
2011Gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Biomarkers in inflammatory bowel disease: current practices and recent advances.
2012Translational research : the journal of laboratory and clinical medicine
Relevant review or meta-analysis for the signal-disease area.
Faecal markers of gastrointestinal inflammation.
2012Journal of clinical pathology
Relevant review or meta-analysis for the signal-disease area.
Diagnosis and classification of Crohn's disease.
2014Autoimmunity reviews
Relevant review or meta-analysis for the signal-disease area.
New serological markers in pediatric patients with inflammatory bowel disease.
2014World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease.
2014World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Probiotics: an update.
2015Jornal de pediatria
Relevant review or meta-analysis for the signal-disease area.
ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease?
2016Digestive diseases (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
Clinical and Phenotypic Differences in Inflammatory Bowel Disease Among Arab and Jewish Children in Israel.
2017Digestive diseases and sciences
Relevant review or meta-analysis for the signal-disease area.
Probiotics and Their Use in Inflammatory Bowel Disease.
2018Alternative therapies in health and medicine
Relevant review or meta-analysis for the signal-disease area.
Review of Saccharomyces boulardii as a treatment option in IBD.
2018Immunopharmacology and immunotoxicology
Relevant review or meta-analysis for the signal-disease area.
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.
2018PloS one
Relevant review or meta-analysis for the signal-disease area.
[Microbiota and inflammatory bowel disease: an update.].
2018Recenti progressi in medicina
Relevant review or meta-analysis for the signal-disease area.
Review article: fungal alterations in inflammatory bowel diseases.
2019Alimentary pharmacology & therapeutics
Relevant review or meta-analysis for the signal-disease area.
Alteration of the Gut Microbiome in Inflammatory Bowel Disease.
2023Digestion
Relevant review or meta-analysis for the signal-disease area.
Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease.
2023Digestion
Relevant review or meta-analysis for the signal-disease area.
Immunoglobulins at the interface of the gut mycobiota and anti-fungal immunity.
2023Seminars in immunology
Relevant review or meta-analysis for the signal-disease area.
The Role of Serological Markers in the Prediction of Disease Course and Response to Therapy in Inflammatory Bowel Disease.
2023Cureus
Relevant review or meta-analysis for the signal-disease area.
Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?
2024Advances in therapy
Relevant review or meta-analysis for the signal-disease area.
A comprehensive guide to assess gut mycobiome and its role in pathogenesis and treatment of inflammatory bowel disease.
2024Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Probiotic Yeasts: A Developing Reality?
2024Journal of fungi (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
The Key Nutrients in the Mediterranean Diet and Their Effects in Inflammatory Bowel Disease: A Narrative Review.
2024Nutrients
Relevant review or meta-analysis for the signal-disease area.
Gut Mycobiome in Inflammatory Bowel Disease: A Systematic Review of Case-Control Studies.
2025Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Probiotics and the intestinal tight junction barrier function.
2025Frontiers in cell and developmental biology
Relevant review or meta-analysis for the signal-disease area.
Neglected kingdoms: the gut virome, mycobiome and their role in inflammatory bowel disease.
2026Gut microbes
Relevant review or meta-analysis for the signal-disease area.